The Irish Pharmaceutical Healthcare Association (IPHA) urges major process reforms in clinical research to help accelerate new medicines development.
The IPHA makes this call as the IPHA Clinical Research Survey 2020 shows Denmark attracts three times as many clinical trials as Ireland. Between 2013 and 2019, Ireland conducted 338 clinical trials across four phases, according to data from clinicaltrials.gov. In Denmark, the number was 918, while Finland recorded 509 clinical trials.
It takes at least two months longer to recruit a patient on a clinical trial in Ireland compared with Denmark and Finland, according to the survey. The wait time in Ireland is, on average, 246 days. The measure is the number of calendar days it takes to recruit a first patient into a trial from the date the company submits to a Recognised Ethics Committee – the international best practice structure for overseeing the conduct of ethical standards in healthcare research.
IPHA outlines the process reforms it believes are needed and this includes the facilitation of sharing best practices across hospitals and demanding consistency whilst approaching clinical research.
Dr Rebecca Cramp, Scientific and Regulatory Affairs Manager at IPHA, says:
“Ireland can have a lead role for clinical trials in Europe. We have a strong base of international biopharmaceutical companies, alongside global clinical leaders, and a willing and adaptive policymaker community. Reforms are needed in the clinical trials process – and, if we get them right, more patients will benefit from breakthrough medicines innovation.”
For more information, please read the press release.